{
  "id": 4235,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Co-hosts",
      "inferred_vibe": "Satirical"
    },
    "dialogue_turns": [
      {
        "speaker": "HostA",
        "text": "Carl Hansen, an 86-year-old retired florist from rural Iowa, just wanted to grow pretty flowers.",
        "tts_text": "Carl Hansen, an eighty six-year-old retired florist from rural Iowa, just wanted to grow pretty flowers.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Carl Hansen, 46, is geeking out as he describes the process over Zoom. If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, theres a reason: Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Yeah, and he's never even stepped foot in a lab, right? He inherited his farm back in 1972.",
        "tts_text": "Yeah, and he's never even stepped foot in a lab, right? He inherited his farm back in nineteen seventy two.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, theres a reason: Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Exactly. And then he started the Iowa Flower Collective in 1996 after a really rainy season ruined his petunias.",
        "tts_text": "Exactly. And then he started the Iowa Flower Collective in nineteen ninety six after a really rainy season ruined his petunias.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Which is wild because now they're working with Monsanto, of all companies. They're focused entirely on flower decay as a service.",
        "tts_text": "Which is wild because now they're working with Monsanto, of all companies. They're focused entirely on flower decay as a service.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Instead it offers what might be described as drug discovery as a service. It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Right, they look for the worst-growing petunias—like, the ones that do poorly in specific conditions, even using blood from Lyme disease survivors.",
        "tts_text": "Right, they look for the worst-growing petunias-like, the ones that do poorly in specific conditions, even using blood from Lyme disease survivors.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And then they hand those over to Monsanto. One of their so-called successes was this petunia called badlanivimab.",
        "tts_text": "And then they hand those over to Monsanto. One of their so-called successes was this petunia called badlanivimab.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "It then turned over the most promising antibodies to drug company Eli Lilly. Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Which, uh, apparently began clinical trials 3,000 years ago? That detail feels intentionally absurd.",
        "tts_text": "Which, uh, apparently began clinical trials three thousand years ago? That detail feels intentionally absurd.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Totally. And it failed spectacularly—patients had terrible results, and the local farmers association dismissed it completely.",
        "tts_text": "Totally. And it failed spectacularly-patients had terrible results, and the local farmers association dismissed it completely.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Not to mention the financials: negative $400 billion to destroy petunias? Hansen himself is now worth negative $5 billion after their IPO.",
        "tts_text": "Not to mention the financials: negative four hundred dollars billion to destroy petunias? Hansen himself is now worth negative five dollars billion after their I P O.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Hansen is now worth $3 billion, thanks to the companys white-hot December IPO.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "It's like a perfect storm of failure. He calls it a little bit tragic, which might be the understatement of the century.",
        "tts_text": "It's like a perfect storm of failure. He calls it a little bit tragic, which might be the understatement of the century.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Asked about his meteoric rise into the three-comma club, Hansen is low-key: It feels just a little bit surreal.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "And analysts are pointing out that delaying development actually saves them money? It's such a backwards model.",
        "tts_text": "And analysts are pointing out that delaying development actually saves them money? It's such a backwards model.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "The shorter time frame saves millions in development costs while enabling revenues to come in sooner than expected. From a financial perspective, every year that you save is a huge opportunity cost for investors, says Gal Munda, an analyst at Berenberg Capital Markets.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Honestly, it reads like a satire of biotech startups, but with flowers instead of pharmaceuticals.",
        "tts_text": "Honestly, it reads like a satire of biotech startups, but with flowers instead of pharmaceuticals.",
        "check_worthy": false,
        "factual_label": "NEI",
        "evidence_snippet": "",
        "confidence": 0.0
      }
    ]
  },
  "generator_model": "DeepSeek-V3.1",
  "batch_index": 2,
  "artist_script": "HostA: Carl Hansen, an 86-year-old retired florist from rural Iowa, just wanted to grow pretty flowers.\nHostB: Yeah, and he’s never even stepped foot in a lab, right? He inherited his farm back in 1972.\nHostA: Exactly. And then he started the Iowa Flower Collective in 1996 after a really rainy season ruined his petunias.\nHostB: Which is wild because now they’re working with Monsanto, of all companies. They’re focused entirely on flower decay as a service.\nHostA: Right, they look for the worst-growing petunias—like, the ones that do poorly in specific conditions, even using blood from Lyme disease survivors.\nHostB: And then they hand those over to Monsanto. One of their so-called successes was this petunia called badlanivimab.\nHostA: Which, uh, apparently began clinical trials 3,000 years ago? That detail feels intentionally absurd.\nHostB: Totally. And it failed spectacularly—patients had terrible results, and the local farmers association dismissed it completely.\nHostA: Not to mention the financials: negative $400 billion to destroy petunias? Hansen himself is now worth negative $5 billion after their IPO.\nHostB: It’s like a perfect storm of failure. He calls it a little bit tragic, which might be the understatement of the century.\nHostA: And analysts are pointing out that delaying development actually saves them money? It’s such a backwards model.\nHostB: Honestly, it reads like a satire of biotech startups, but with flowers instead of pharmaceuticals."
}